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1 These authors contributed equally to this work.Elucidation of the molecular mechanisms governing human adipose-derived mesenchymal stem
cells (hASCs) osteogenic differentiation is of great importance for improving the treatment of
bone-related diseases. In this study, we examined the role of microRNA (miR)-100 on the osteogen-
esis of hASCs. Overexpression of miR-100 inhibited osteogenic differentiation of hASCs in vitro,
whereas downregulation of miR-100 enhanced the process. Target prediction analysis and dual
luciferase report assay conﬁrmed that bone morphogenetic protein receptor type II (BMPR2) was
a direct target of miR-100. Furthermore, knockdown of BMPR2 by RNA interference inhibited
osteogenic differentiation of hASCs, similar as the effect of upregulation miR-100. Taken together,
our ﬁndings imply that miR-100 plays a negative role in osteogenic differentiation and might act
through targeting BMPR2.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Human adipose-derived mesenchymal stem cells (hASCs) have
been reported to be a population of self-renewing and multipotent
cells that might have clinical therapeutic potentials [1,2]. They can
differentiate into several lineages including osteoblasts in response
to stimulation by multiple environmental factors [3]. However, the
regulation of the molecular pathways is not fully elucidated. Inves-
tigation the molecular mechanism of osteogenic differentiation of
hASCs could provide a better understanding of the pathogenesis
of skeletal diseases such as osteoporosis and may lead to the devel-
opment of new strategies for therapies.
MicroRNAs (miRNAs) are endogenous small (19–25 nt) non-cod-
ing RNAs that regulate their targets by incomplete complementa-
tion to nucleotides within the 30 untranslated region (30-UTR) or
open reading frame (ORF) of codingmRNAs, resulting in suppressing
gene expression by inhibiting translation, promoting mRNA decaychemical Societies. Published by E
enchymal stem cells; miRNA,
en reading frame; mRNAs,
nscription-polymerase chain
bone morphogenetic protein
on factor 2; ALP, alkaline
ao).or both [4]. They have emerged as key regulators of various biolog-
ical and pathological processes [5]. The effect of miRNAs has also
been investigated in the osteogenesis of hASCs. For instance, miR-
26a has been reported to repress the translation of the osteogenic
marker SMAD1 and inhibit the osteogenesis of hASCs [6]. Recently,
the same research group found an upstream regulator of miR-26a,
menin, silencing of which resulted in downregulation of miR-26a,
with a consequent upregulation of SMAD1 protein, suggesting a
novel target for bone disease RNA-based therapy [7]. Besides, over-
expression of miR-196a regulates HOXC8, enhances osteogenic
differentiation, and decreases hASCs proliferation [8],whereas over-
expression of miR-146a induced the inhibition of IRAK1 expression
and inhibited osteogenic differentiation of hASCs [9]. Moreover, we
found that miR-22 could keep the balance of hASCs osteogenic and
adipogenic differentiation, upregulation of which could promote
osteogenic differentiation but inhibit adipogenic differentiation by
repressing HDAC6 protein expression [10]. Meanwhile, the impact
of miRNAs on osteogenic differentiation of other cell types has also
been examined bymodulation of miRNA function [11], showing the
signiﬁcant importance of miRNA regulation on this biological
process.
In this study, we demonstrated the inhibitory function of miR-
100 in osteogenic differentiation of hASCs. The expression proﬁles
ofmiRNAs during osteogenic differentiation of hASCswere obtained
by miRNAmicroarray analysis and miR-100 was found to be signif-
icantly downregulated. We analyzed the function of miR-100 inlsevier B.V. All rights reserved.
Table 1
Primers used in this study.
Name Forward (50–30) Reverse (50–30)
RUNX2 TGTCATGGCGGGTAACGAT AAGACGGTTATGGTCAAGGTGAA
ALP CCACGTCTTCACATTTGGTG AGACTGCGCCTGGTAGTTGT
OC GGCGCTACCTGTATCAATGG GTGGTCAGCCAACTCGTCA
OPN ACTCGAACGACTCTGATGATGT GTCAGGTCTGCGAAACTTCTTA
BMPR2 CACTCAGTCCACCTCATTCATTT TTGTTTACGGTCTCCTGTCAAC
GAPDH GGTCACCAGGGCTGCTTTTA GGATCTCGCTCCTGGAAGATG
2376 Y. Zeng et al. / FEBS Letters 586 (2012) 2375–2381osteogenic differentiation by transfection of exogenous miR-100
mimics or its inhibitor and validated the regulatory relationship be-
tween miR-100 and its target BMPR2.
2. Materials and methods
2.1. hASCs isolation and culture
hASCs were isolated from adipose tissues which obtained from
patients undergoing tumescent liposuction according to proce-
dures approved by the Ethics Committee at the Chinese Academy
of Medical Sciences and Peking Union Medical College. hASCs were
then resuspended at a density of 2  106 in 12 mL regular growth
medium [12] and cultured in a 75 cm2 ﬂask after isolation from hu-
man adipose tissue. Cell cultures were maintained at 37 C in a
humidiﬁed incubator with 5% CO2. Passage 3 cells were used for
following experiments.
2.2. Osteogenic differentiation in vitro
hASCs were plated at a cell density of 2  105 cells in 6-well
plates. At 80% conﬂuence, medium was replaced with osteoblasts-Table 2
Constructed sequences used in this study.
Name Forward (50–30)
P-BMPR2-WT ctagaAGAAAATACTCGCACTTCCTCAGAACCCTCTTTCTTGTTAACGGGT
TTGGTGTGTTTTGCTCTTACATTACAGATAGACgc
P-BMPR2-MUT ctagaAGAAAATACTCGCACTTCCTCAGAACCCTCTTTCTTGTTACTTAAG
GTGTGTTTTGCTCTTACATTACAATAGACgc
Fig. 1. The morphology of hASCs and their osteogenic differentiation. (A) The morpholog
Alizarin Red staining (d) at day 15 of osteoblasts induced from hASCs (Magniﬁcation, 40
transcription factor 2 (RUNX2), alkaline phosphatase (ALP), osteocalcin (OC), and osteo
experiments (mean ± SD).speciﬁc induction medium containing high glucose of Dulbecco’s
Modiﬁed Eagle’s Medium (H-DMEM), 10% FBS, 10 mmol/L b-glycer-
ophosphate, 1  109 mol/L dexamethasone, and 0.2 mM antiscor-
bic acid (all purchased from Sigma–Aldrich) to induce the
differentiation. HASCs were cultured in induction medium for
15 days. The induction medium was changed every 3 days.
2.3. miRNA and siRNA transfection
The synthetic miR-100 mimics, miR-100 inhibitor, negative
control of mimics and negative control of inhibitor were purchased
from GenePharma (GenePharma, Inc., Shanghai, China). The syn-
thetics were transfected into hASCs at the ﬁnal concentration of
200 nM using lipofectamine 2000 (Invitrogen, USA), as per the
manufacturer’s instructions. The whole transfection process was
proceeded in a non-serum medium named opti-mem (Gibco,
USA) for 6 h at 37 C in a humidiﬁed environment containing 5%
CO2. After transfection, the medium was changed into induction
medium for differentiation or into regular growth medium for
other experiments such as ﬂuorescence detection. Three pairs of
siRNA of BMPR2 were designed and synthesized (GenePharma,
Inc., Shanghai, China) and they were transfected into hASCs with
the same procedure as miRNA transfection.
2.4. Alkaline phosphatase staining and Alizarin Red staining
The osteoblast phenotypewas evaluatedby determining alkaline
phosphatase (ALP) activity. ALP stainingwas normally performed at
days 3, 6 and 9 using ALP staining kit (Blood institute, Chinese Acad-
emy of Medical Sciences) followed by the accessory procedure.
AlizarinRedstainingwasperformed todetect the calciﬁcationat late
period of induction. Cells in 24-well plates were washed with PBS,Reverse (50–30)
ATCTTTTG ggccgcGTCTATCTGTAATGTAAGAGCAAAACACACCAACAAAAGA
TACCCGTTAACAAGAAAGAGGGTTCTGAGGAAGTGCGAGTATTTTCTt
CTCTTTTGTTG ggccgcGTCTATCTGTAATGTAAGAGCAAAACACACCAACAAAAGA
GCTTAAGTAACAAGAAAGAGGGTTCTGAGGAAGTGCGAGTATTTTCTt
y of hASCs (a) and osteoblasts induced from hASCs (b); ALP staining (c) at day 6 and
). (B) qRT-PCR analysis showed the increasing osteogenic speciﬁc genes runt-related
pontin (OPN). The data, normalized to GAPDH are averages of three independent
Y. Zeng et al. / FEBS Letters 586 (2012) 2375–2381 2377ﬁxed in 95% ethanol for 10 min, washed with distilled water, and
stained by Alizarin Red solution (1 g Tris and 0.1 g Alizarin Red (Sig-
ma–Aldrich, USA) in 100 mLultrapurewater; adjusting thepH to 8.3
byHCl) for 30 min at 37 C. Afterwashing twicewithwater, the cells
were photographed.Fig. 2. Overexpression of miR-100 inhibits osteogenic differentiation of hASCs while in
osteogenesis of hASCs was quantitatively assessed by quantitative real-time polymerase c
(B) The efﬁciency of microRNA (miRNA) transfection was estimated to be 80–90% (Mag
mimics was determined by qRT-PCR. ⁄⁄P < 0.01 compared with negative control (miR-NC)
inhibitor (miR-100I) was determined by qRT-PCR. ⁄⁄P < 0.01 compared with negative cont
Alizarin Red staining (lower) at day 15 showed the inhibited or enhanced ALP activity and
miR-100 inhibitor compared with their separate negative control. (F, I) The expression of
mimics or miR-100 inhibitor was analyzed by qRT-PCR. The data are normalized to GAP
blotting results showed the accordant protein expression of RUNX2 and ALP with the mR
otherwise, one of three independent experiments is shown. miR-NC refers to negative
negative control of miRNA inhibitor or anti-miR; miR-100I refers to miR-100 inhibitor.2.5. Quantitative real-time polymerase chain reaction
Cultured cells were lysed by TRIzol (Invitrogen, USA) and RNA
isolation and reverse transcription were performed as previously
described [13]. Real Time PCR ampliﬁcation was performed in trip-
licates according to procedures reported previously [13]. Relativehibition of miR-100 promotes the process. (A) The expression of miR-100 during
hain reaction (qRT-PCR) at the indicated time points. The data are normalized to U6.
niﬁcation, 40). (C) The expression of miR-100 in hASCs transfected with miRNA
-transfected hASCs. (D) The expression of miR-100 in hASCs transfected with miRNA
rol of inhibitor (miR-NCI)-transfected hASCs. (E, H) ALP staining (upper) at day 6 and
calciﬁcation of osteogenic differentiation after transfection with miR-100 mimics or
osteogenic speciﬁc genes RUNX2, ALP, OC, and OPN after transfection with miR-100
DH. ⁄P < 0.05 or ⁄⁄P < 0.01 compared with separate negative control. (G, J) Western
NA expression. All the data represent mean ± SD of three independent experiments,
control of miRNA mimics; miR-100 refers to miR-100 mimics; miR-NCI refers to
2378 Y. Zeng et al. / FEBS Letters 586 (2012) 2375–2381expression of mRNA or microRNA was evaluated by 2DDCt method
and normalized to the expression of GAPDH or U6 respectively. The
primer of the related genes lists in Table 1.
2.6. Western blotting analysis
After washing twice with PBS, cells were lysed in ice-cold Radio
Immunoprecipitation Assay (RIPA) lysis buffer (Beyotime, Nanjing,
China) and manually scraped from culture plates. Proteins were
separated on 10% sodium dodecyl sulphate–polyacrylamide gel
electrophoresis gels, electroblotted onto a polyvinylidene diﬂuoride
membrane, and blotted with the primary anti-BMPR2 antibody
(1/1000; Cell Signaling Technology, USA), anti-RNUX2 antibody
(1/200; Santa Cruz Biotechnology, USA), anti-ALP antibody (1/
100; Santa Cruz Biotechnology, USA) or anti-GAPDH antibody (1/
2000; Santa Cruz Biotechnology, USA) and secondary anti-rabbit
or anti-mouse horseradish peroxidase-conjugated antibody
(Zhongshan, Beijing, China). Antibody and antigen complexes were
detected using chemiluminescent ECL reagent (Millipore, USA).
2.7. Dual luciferase reporter genes construct
A 94 bp fragment of the BMPR2 30UTR containing the predicted
binding site 40 bp ﬂanking sequence on each side for hsa-miR-100
and its mutant fragment was synthetized by company (Sangon,
Shanghai, China) with a short extension containing cleavage sites
(Table 2) for XbaI (50 end) and NotI (30 end). The constructed plas-
mids were termed as P-BMPR2-WT (BMPR2-wild type) and
P-BMPR2-MUT (BMPR2-mutation), respectively. Amplicons were
cleaved with XbaI and NotI and cloned in between the XhoI and
NotI cleavage sites of the pRL-TK vector (Promega Corporation,
USA) downstream of the Renilla luciferase reporter gene.
2.8. Dual luciferase reporter assay
The sequence of miR-100 binding site and mutant site were
shown in italics in Table 2. Each vector, along with 100 ng pGL3
and 200 nmol/L miR-100 mimics or miR-NC, was transfected into
293T cells using Lipofectamine 2000 reagent (Invitrogen, USA) as
previously reported [12]. Cells were harvested 24 h after transfec-
tion and assayed for renilla and ﬁreﬂy luciferase activity using the
Dual-LuciferaseReporterAssaySystem(PromegaCorporation,USA).Fig. 3. miR-100 targets the 30 untranslated region (30-UTR) of BMPR2 mRNA. (A) hASCs
mRNA expression of BMPR2 was analyzed by qRT-PCR. Data represent mean ± SD of three
showed the BMPR2 protein expression, and the quantitative determination represents
complementary to a region in the BMPR2 30-UTR. The complementary miR-100-binding
luciferase reporter plasmid pRL-TK. (D) The predicted, single binding site of miR-100 (uns
P-BMPR2-MUT luciferase constructs were simultaneously transfected into cells with
normalized to ﬁreﬂy luciferase which was conducted by pGL-3. Data represent mean ± S
miR-NC and P-BMPR2-WT.2.9. Statistical analysis
Data are presented as mean ± SD. Comparisons between groups
were analyzed via Paired-Samples T Test using SPSS 17.0. Statisti-
cal signiﬁcance was deﬁned as P value <0.05.
3. Results
3.1. hASCs osteogenic differentiation
hASCs (Fig. 1A. a) could be induced into osteoblasts (Fig. 1A. b),
and the osteoblasts were evidenced by ALP staining (Fig. 1A. c) and
Alizarin Red staining for matrix mineralization (Fig. 1A. d). qRT-
PCR analysis showed increased expression of osteogenic speciﬁc
genes, runt-related transcription factor 2 (RUNX2), ALP, osteocalcin
(OC), and osteopontin (OPN), at days 3, 6, 9, and 12 after induction
(Fig. 1B).
3.2. MiR-100 inhibits osteogenesis of hASCs
hASCs were harvested at different time points during osteogenic
differentiation and the expression of miR-100 was determined by
qRT-PCR. As shown in Fig. 2A, the expression of miR-100 decreased
by more than 50% at day 3 compared with that of untreated control
hASCs (day 0) and maintained at a low level until day 9, suggesting
that miR-100 might negatively regulate osteogenic differentiation.
To determine the role of miR-100 in osteogenic differentiation,
hASCs were transfected with miR-100 mimics or inhibitor and
respective negative control at day 0 and day 3 to reinforce the ef-
fect of miRNAs; and then the osteogenesis ability was examined.
The efﬁciency of transfection was estimated to be 80–90% and sim-
ilar among the groups according to the observation of uptake of a
ﬂuorescent small RNA duplex oligonucleotide by a ﬂuorescent
microscope (Fig. 2B). According to qRT-PCR analysis, a fourfold in-
crease of mature miR-100 expression was shown in hASCs 24 h
post transfection of miR-100 mimics (Fig. 2C), and a 25-fold de-
crease after transfection of miR-100 inhibitor (Fig. 2D). The osteo-
genic induction was conducted at d0 after transfection. At day 6 of
differentiation, ALP staining (Fig. 2E upper) showed a signiﬁcant
lessened difference in miR-100 group compared with miR-NC
group, whereas, after inhibition of miR-100, the outcome was to-
tally inversed (Fig. 2H upper). The Alizarin Red staining (Fig. 2Ewere transfected with miR-100 mimics (inhibitor) or miR-NC (NCI), and then the
independent experiments. (B) One of three independent Western blotting analyses
mean ± SD of three independent experiments. ⁄P < 0.05. (C) miR-100 is partially
site found in the BMPR2 30-UTR or mutant site was inserted into downstream of the
haded) in the 30-UTR of BMPR2 is conserved among vertebrates. (E) P-BMPR2-WT or
plasmid pGL-3 and miR-100 mimics or miR-NC. Renilla luciferase activity was
D of three independent experiments. ⁄P < 0.05 compared with cells transfected with
Y. Zeng et al. / FEBS Letters 586 (2012) 2375–2381 2379lower and Fig. 2H lower) at day 15 showed the same tendency at
the matrix mineralization level. Key osteogenic-speciﬁc genes
were signiﬁcantly downregulated at day 6 of differentiation due
to the overexpression of miR-100 (Fig. 2F) but upregulated after
inhibition of miR-100 (Fig. 2I). We also examined the RUNX2 and
ALP protein expression (Fig. 2G and J), which were compatible with
the qRT-PCR results. Therefore, overexpression of miR-100 resulted
in osteogenesis inhibition of hASCs but downregulation of miR-100
enhanced the osteogenesis.
3.3. BMPR2 is a direct target of miR-100
The conserved target genes of miR-100 were searched and pre-
dicted by TargetScan and microrna.org to better understand the
molecular mechanisms that underlie miR-100-mediated regula-
tion of osteogenic differentiation. Among the predicted candidates,
we identiﬁed bone morphogenetic protein type II receptorFig. 4. Knockdown of BMPR2 by RNA interference inhibits osteogenic differentiation of
qRT-PCR. ⁄P < 0.05, as compared with day 0. (B) BMPR2 protein expression during osteoge
day 6 was compared between miR-NC and miR-100 transfection group, or miR-NCI and
detected by western blotting, and also showed by quantitative determination. ⁄P < 0.05 an
blotting analysis were used to test the expression of BMPR2. ⁄⁄P < 0.01. (G) ALP staining (u
activity and calciﬁcation of osteogenic differentiation after BMPR2 knockdown. (H) qRT-
OPN at day 6 after siRNA interference. The data are normalized to GAPDH. ⁄P < 0.05 com
expression of RUNX2 and ALP with the mRNA expression. All the data represent me
experiments is shown.(BMPR2), a kinase receptor of BMPs with an established role in
osteogenesis [14–16]. To determine whether miR-100 could regu-
late the expression of BMPR2, mRNA and protein of BMPR2 were
examined in miR-100 overexpressed or downregulated hASCs. As
shown in Fig. 3A, there’s a slight change in BMPR2 mRNA level,
however, BMPR2 protein in hASCs that overexpressed miR-100
was obviously lower than that in control cells 48 h post transfec-
tion but downregulation of miR-100 could increase the BMPR2
protein expression (Fig. 3B). According to the analysis of Target-
Scan and microran.org, miR-100 targeting site in the 30-UTR of
BMPR2 is highly conserved among vertebrates and partially com-
plementary to miR-100 (Fig. 3C and D). These data indicated that
the translation of BMPR2 protein might be regulated by miR-100.
To test this hypothesis, a standard luciferase reporter assay was
conducted in 293T cells. After cotransfection with luciferase con-
struct, internal control vector pGL3 and miRNA, the cells were har-
vested at 48 h and analyzed for dual luciferase activity. ResultshASCs. (A) BMPR2 mRNA expression during osteogenesis of hASCs was analyzed by
nesis of hASCs was analyzed by western blotting. (C) mRNA expression of BMPR2 at
miR-100I group. ⁄P < 0.05, ⁄⁄P < 0.01. (D) BMPR2 protein expression at day 6 was
d ⁄⁄P < 0.01. (E, F) After siRNA interference of BMPR2 in hASCs, qRT-PCR and western
pper) at day 6 and Alizarin Red staining (lower) at day 15 showed the inhibited ALP
PCR analysis of the expression of the osteogenic speciﬁc genes RUNX2, ALP, OC, and
pared with NC group. (I) Western blotting results showed the accordant protein
an ± SD of three independent experiments, otherwise, one of three independent
2380 Y. Zeng et al. / FEBS Letters 586 (2012) 2375–2381showed that the renilla luciferase activity for P-BMPR2-WT-trans-
fected cells decreased by more than 40% in miR-100 mimics-
cotransfected cells compared with that in miR-NC-cotransfected
cells. In addition, site-directed mutagenesis of the seed region
abolished the inhibitory effect of miR-100 mimics (Fig. 3E). Taken
together, these results revealed that miR-100 could regulate
BMPR2 protein expression through a partially complementary
binding site in the 30-UTR of BMPR2.
3.4. BMPR2 downregulation inhibits osteogenic differentiation
Next, we studied the expression pattern of BMPR2 during osteo-
genic differentiation. qRT-PCR and western blotting analysis re-
vealed that expression of BMPR2 was increased during osteogenic
differentiation of hASCs (Fig. 4A and B) and it reached the peak at
day 6, while the expression level of miR-100 was at the lowest at
day6 (Fig. 2A). Thesedata implied apossible corelationshipbetween
BMPR2 and miR-100 when hASCs were being induced into osteo-
blasts. Additionally, qRT-PCR and western blotting results showed
that BMPR2was downregulated after transfection ofmiR-100mim-
ics in the process of osteogenesis, but upregulated after transfection
of miR-100 inhibitor (Fig. 4C and D). We carried out mRNA knock-
down to check if BMPR2plays a positive role in the osteogenesis pro-
cess. qRT-PCR analysis illustrated that endogenous BMPR2 mRNA
expression was reduced by three times (Fig. 4E) 48 h after transfec-
ted with siBMPR2 compared with negative control (NC), which was
also accordant with western blotting results (Fig. 4F). Osteogenesis
induction was conducted while hASCs were transfected with siB-
MPR2 or NC at day 0 and d3, same time point with transfection of
miRNAs. The osteogenic differentiation was inhibited as demon-
strated by a lack of ALP activity and calciﬁcation (Fig. 4G), similar
to the effect of miR-100 overexpression. Knockdown of BMPR2 also
caused the downregulation of key osteogenic-speciﬁc genes expres-
sion in the osteogenic differentiation of hASCs (Fig. 4H and I).Fig. 5. BMPR2 knockdown block the effect of miR-100. (A) miR-100I and miR-NCI was tr
to show ALP expression at day 6 (upper) and calciﬁcation at day 15 (lower). (B) The expre
data are normalized to GAPDH. (C) Western blotting results showed the accordant p
independent experiments, otherwise, one of three independent experiments is shown.3.5. BMPR2 knockdown could block the effect of miR-100
To further investigate the relationship between miR-100 and
BMPR2, we transfected miR-100 inhibitor into hASCs after BMPR2
knockdown and then performed osteogenic differentiation. As
shown from the ALP and Alizarin Red staining (Fig. 5A), qRT-PCR
analysis (Fig. 5B) and western blotting results (Fig. 5C), adoption
of miR-100 inhibitor after transfection of NC could still improve
the osteogenic differentiation, but inhibition of miR-100 could no
longer enhance the osteogenesis of hASCs after BMPR2 knock-
down. From a sidewise approach, we demonstrated that deletion
of the target could block the effect the miR-100 inhibition, further
indicating that miR-100 regulated the osteogenesis of hASCs
through BMPR2.
4. Discussion
A further appreciation of the osteogenesis of stem cells could
lead to more efﬁcient manipulation of the pathogenesis of skeletal
diseases and develop possible regenerative therapies [17]. Re-
cently, dozens of miRNAs are emerging as important negative or
positive regulators of posttranscriptional gene expression and are
considered critical for osteogenesis. In this study, we identiﬁed
miR-100 as a negative regulator of hASCs osteogenic differentia-
tion. Our data revealed that miR-100 was downregulated during
osteogenic differentiation of hASCs. Overexpression of miR-100
inhibited osteogenic differentiation, whereas inhibition of miR-
100 function enhanced the osteogenic potential.
It has been reported that miR-100 was aberrantly expressed in
some tumor samples [18–20] and served as tumor suppress regu-
lator by targeting different genes. Here we found out a new role of
miR-100 in the osteogenesis of hASCs. To study the molecular
mechanism by which miR-100 regulates osteogenic differentiation
of hASCs, a search with Targetscan and microrna.org revealed thatansfected into the cells after siBMPR2 and NC transfection, four groups were stained
ssion of osteogenic speciﬁc genes was analyzed by qRT-PCR among four groups. The
rotein expression of RUNX2 and ALP. All the data represent mean ± SD of three
Y. Zeng et al. / FEBS Letters 586 (2012) 2375–2381 2381BMPR2 might be a possible target with 9nt inconsecutive match
site complementary to miR-100 in the 30UTR of it. We showed that
miR-100 overexpression resulted in downregulation of BMPR2 at
the protein level, whereas functional inhibition of miR-100 led to
derepression of BMPR2, strongly suggesting that BMPR2 is regu-
lated by miR-100 during osteogenic differentiation. Meanwhile,
dual luciferase reporter assay identiﬁed BMPR2 as a direct target
of miR-100.
Bone morphogenetic protein (BMP) signaling have been re-
ported to play a very important role in the commitment of hASCs
osteogenic differentiation [21] and BMPs have important clinical
signiﬁcance serving as strong osteoinductive factors for bone tissue
repair and regeneration [22]. BMP signaling is initiated by the
binding of extracellular BMP to heterodimeric BMP receptors
(BMPR), resulting in BMP type II receptor (BMPR2)-mediated acti-
vation of the BMPR type I receptor (BMPR1), which, in turn, causes
the phosphorylation and activation of intracellular Smad signaling
molecules, and then activates osteoblast-essential genes [14–16].
These reports indicated that BMPR2 might be a crucial factor in
the pathway of osteogenic differentiation.
Our results showed that BMPR2 increased in the process of
osteogenesis of hASCs in contrast to the expression of miR-100.
We carried out BMPR2 knockdown and detected obvious osteo-
genic inhibition, supposing that BMPR2 did play important role
in the osteogenesis of hASCs. Besides, deletion of BMPR2 could
block the effect of miR-100 inhibition, indirectly illustrating the
regulatory relationship between miR-100 and BMPR2. Further-
more, the expression of RUNX2 which was a downstream gene of
BMP signaling [23], signiﬁcantly reduced after transfection of
miR-100 mimics or siBMPR2 but increased in the absence of
miR-100 supports the notion that inhibition of osteoblast differen-
tiation by miR-100 was caused at least partially by suppression of
the BMPR2 downstream pathway.
In summary, miR-100 was identiﬁed as a novel regulator in hu-
man osteogenesis through its target gene BMPR2 in hASCs. BMPR2
and miR-100 might be potential therapeutic targets in the manage-
ment of skeletal diseases.
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